Jakub B.
- Country
- Poland
- Department
- N/A
Research Overview
- Efficacy and Safety Evaluation of Rezpegaldesleukin in Biologic-Naive Adults with Moderate-to-Severe Atopic Dermatitis: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Four-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitor-Associated Major Bleeding in Patients on DOAC Therapy
- Efficacy and Safety Evaluation of RO7790121 Induction Therapy in Moderately to Severely Active Ulcerative Colitis: A Phase III Multicenter Double-Blind Placebo-Controlled Study
Data & Insights
Has run more than one trial at 55 of 171 partner sites.
Specializations
Dermatology Research
The investigator specializes in the treatment of moderate-to-severe atopic dermatitis, with particular focus on novel biological therapies for inflammatory skin conditions.
- Biologic-naive patient treatments
- Inflammatory skin disorders
- Novel therapeutic approaches
Their work involves evaluating innovative treatments for patients who have not previously received biological therapy.
Gastroenterology Studies
The investigator conducts research in ulcerative colitis management, focusing on oral therapeutic interventions for patients with mild to moderate disease activity.
- Clinical remission assessment
- Inflammatory bowel disease treatments
- Mesalazine formulation studies
Their research encompasses endoscopic and symptomatic remission evaluation in gastrointestinal conditions.
Oncology Focus
The investigator specializes in treating advanced and metastatic breast cancer, particularly focusing on hormone receptor-positive, HER2-negative cases.
- Endocrine therapy resistance
- Novel therapeutic compounds
- Advanced breast cancer treatment
Their research includes evaluation of new treatment options for patients who have progressed after standard therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.